Shots:

• The MOVe-OUT study evaluates molnupiravir (MK-4482, EIDD-2801) vs PBO in 1433 patients with COVID-19
• The results showed a reduction in the risk of hospitalization or death (6.8% vs 9.7%), relative & absolute risk reduction of 30% & 2.0%. The AEs profile remained consistent with the profile reported at the planned interim analysis while interim analysis & additional analyses support the efficacy & overall favorable benefit-risk assessment of molnupiravir
• The companies conducted a development program for molnupiravir. Additionally, Merck’s application is under US FDA & EMA's review for EUA & marketing authorization to support the decision-making on the use of molnupiravir

 Ref: Business Wire | Image: Merck